Cytokinetics Inc (CYTK)
54.70
-1.26
(-2.25%)
USD |
NASDAQ |
Nov 14, 16:00
54.71
+0.01
(+0.02%)
Pre-Market: 20:00
Cytokinetics Cash from Financing (Quarterly): 3.425M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.425M |
| June 30, 2024 | 821.01M |
| March 31, 2024 | 103.79M |
| December 31, 2023 | 168.80M |
| September 30, 2023 | 54.22M |
| June 30, 2023 | 5.475M |
| March 31, 2023 | -7.177M |
| December 31, 2022 | 29.88M |
| September 30, 2022 | 389.02M |
| June 30, 2022 | 3.416M |
| March 31, 2022 | 93.85M |
| December 31, 2021 | 19.51M |
| September 30, 2021 | 300.90M |
| June 30, 2021 | 3.175M |
| March 31, 2021 | -3.596M |
| December 31, 2020 | 3.641M |
| September 30, 2020 | 226.33M |
| June 30, 2020 | 4.16M |
| March 31, 2020 | -0.011M |
| December 31, 2019 | 121.12M |
| September 30, 2019 | 11.86M |
| June 30, 2019 | 22.40M |
| March 31, 2019 | 4.416M |
| December 31, 2018 | 0.451M |
| September 30, 2018 | 10.23M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.978M |
| March 31, 2018 | -0.524M |
| December 31, 2017 | 2.194M |
| September 30, 2017 | 1.434M |
| June 30, 2017 | 106.56M |
| March 31, 2017 | 115.73M |
| December 31, 2016 | 0.715M |
| September 30, 2016 | 0.727M |
| June 30, 2016 | 0.589M |
| March 31, 2016 | 14.86M |
| December 31, 2015 | 23.64M |
| September 30, 2015 | 0.164M |
| June 30, 2015 | 0.041M |
| March 31, 2015 | 0.065M |
| December 31, 2014 | 9.134M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.035M |
| March 31, 2014 | 39.78M |
| December 31, 2013 | 7.516M |
| September 30, 2013 | -0.516M |
| June 30, 2013 | 7.483M |
| March 31, 2013 | 0.005M |
| December 31, 2012 | 0.025M |
| September 30, 2012 | -0.412M |
| June 30, 2012 | 56.05M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-7.177M
Minimum
Mar 2023
821.01M
Maximum
Jun 2024
117.05M
Average
24.70M
Median
Cash from Financing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 102.76M |
| Biomarin Pharmaceutical Inc | -499.12M |
| Catalyst Pharmaceuticals Inc | -5.974M |
| Sarepta Therapeutics Inc | 13.76M |
| Ocugen Inc | 0.045M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -101.50M |
| Cash from Investing (Quarterly) | -45.05M |
| Free Cash Flow | -407.05M |
| Free Cash Flow Per Share (Quarterly) | -0.8684 |
| Free Cash Flow to Equity (Quarterly) | -103.27M |
| Free Cash Flow Yield | -6.96% |